








key: cord-311523-erntrh3p
authors: Gisondi, P; Piaserico, S; Conti, A; Naldi, L
title: Dermatologists and SARS‐CoV‐2: The impact of the pandemic on daily practice
date: 2020-04-22
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16515
sha: 
doc_id: 311523
cord_uid: erntrh3p

Since the first case of “pneumonia of unknown aetiology” was diagnosed at the Wuhan Jinyintan Hospital in China on 30 December 2019, what was recognised thereafter as “severe acute respiratory syndrome coronavirus 2” (SARS‐CoV‐2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease‐19 (COVID‐ 19) and satisfying the epidemiological criteria for a label of “pandemic.” The ongoing SARS‐CoV‐2 pandemic is having a huge impact on dermatological practice including the marked reduction of face‐to‐face consultations in favour of teledermatology, the uncertainties concerning the outcome of COVID‐19 infection in patients with common inflammatory disorders such as psoriasis or atopic dermatitis receiving immunosuppressive/immunomodulating systemic therapies; the direct involvement of dermatologists in COVID‐19 care for patients assistance and new research needs to be addressed. It is not known yet, if skin lesions and derangement of the skin barrier could make it easier for SARS‐CoV‐2 to transmit via indirect contact; it remains to be defined if specific mucosal or skin lesions are associated with SARS‐CoV‐2 infection, although some unpublished observations indicate the occurrence of a transient varicelliform exanthema during the early phase of the infection. SARS‐CoV‐2 is a new pathogen for humans that is highly contagious, can spread quickly, and is capable of causing enormous health, economic and societal impacts in any setting. The consequences may continue long after the pandemic resolves, and new management modalities for dermatology may originate from the COVID‐19 disaster. Learning from experience may help to cope with future major societal changes.

Since the first case of "pneumonia of unknown aetiology" was diagnosed at the Wuhan Jinyintan Hospital in China on 30 December 2019, what was recognised thereafter as "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 and satisfying the epidemiological criteria for a label of "pandemic," broadly defined as the uncontained spread of an infection in multiple regions [1] . As of 24 March 2020, more than 420,000 cases has been identified worldwide, and almost 19,000 deaths have occurred. After China, the area more severely affected nowadays is Europe, with Italy having the dubious record of the number of deaths [2] .

SARS-CoV-2 is a zoonotic single-stranded RNA virus of the Coronaviridae family, which has crossed species to infect humans, as previously occurred for the virus of the "severe Airborne spread, per se, is not a major route of transmission. Faecal shedding has been demonstrated in some patients, but oro-fecal transmission is not recognised as a relevant driver of infection [4] . Transmission of SARS-CoV-2 mainly occurs in households and other close settings. Nosocomial outbreaks have been reported [5] . Disease presentation can range from no symptoms to severe pneumonia and death ( Table 1 ). The mean incubation period is 5-6 days (range 1-14 days) and the virus can be isolated from the nasopharynx 1-2 days prior to symptom onset. About 90% of people have mild disease and recover [6] . A small proportion has a severe or critical condition. The proportion of truly asymptomatic people remains to be determined. Transmission during an asymptomatic stage does not seem to play a relevant role in spreading the virus.

Individuals at higher risk for severe disease include people aged over 60 years and those with underlying conditions such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer [3, 6] . The disease in children is unapparent or mild. To date, the management of infection has been largely supportive [3, 5, 7] . Case

This article is protected by copyright. All rights reserved fatality rates, i.e., the proportion of deaths from the disease compared to the total number of people diagnosed during a certain period of time, varies, among the others, with location, intensity of transmission, demography of the population, health service organization, and modalities adopted to identify cases. The estimates range from 0.3% in Germany to about 10% in Italy [2]. SARS-CoV-2 is a new virus to humans, and no immunization exists in the population at large. Hence, the virus spreads with astonishing speed. The basic reproduction number (i.e., the number of cases one infected individual generates), R0, has been estimated to range between 1.4 to 3.9 according to the mitigating measures adopted, and the epidemic in the early phase in China was doubling every 6.4 days [3, 7, 8] . Some model predictions indicate that millions of people may be infected by the end of 2020. There is evidence that public health interventions can reduce and even interrupt transmission.

These measures must fully incorporate immediate case detection and isolation, rigorous close contacts tracing with quarantine, and direct population engagement (Table 2) [9] [10] [11] . Contents of educational interventions should include social distancing measures and personal protection strategies such as hand hygiene.

The on going pandemic is having a huge impact on dermatological practice. We are making specific reference to Italy, but the situation is similar to what is happening in other countries (personal communications and [12]).

A significant reduction of outpatient dermatological visits both in public hospitals and in private practice offices is registered in most countries. In Italy, the reduction of dermatological consultations is approximately 80-90%. Such a marked reduction also applies to medical specialities other than dermatology. Most hospitals have postponed appointments for elective surgery and non-urgent visits to avoid people moving form home and to focus on COVID-19 management. In Italy, the reduction is also one of the consequences of the legislative decree of the Italian prime minister #IoRestoaCasa (translated: I stay at home) recommending the closure of any commercial activities all over Italy, except for pharmacies, groceries and other essential services [13] . Citizens are not allowed to leave their homes unless there is the need of going to work (such as in the case of health workers), for urgent health reasons or the purchase of necessary goods.

Triage is made before any patient attends a health consultation looking for any respiratory symptom or fever. In case of symptoms the patient is put in a separate area.

This article is protected by copyright. All rights reserved In this situation, remote working is boosted, and telemedicine -that is defined as ''the remote diagnosis and treatment of patients by means of telecommunications technology'' -could be very appropriate [14] . By practicing teletriage, which prioritizes in-person clinic visits for patients with conditions associated with greater morbidity or mortality and uses telemedicine for the rest, the delivery of dermatologic care can be pursued during the pandemic [15] [16] [17] [18] . Dermatology Forum and the American Academy of Dermatology guidelines [21] ). The safety of initiating immunosuppressant medications during the pandemic is questionable [22] . The benefit-to-risk ratio of any immunosuppressive therapeutic intervention should be carefully weighted in dermatological patients on a case-to-case basis. Individuals over the age of 60 years and/or patients with comorbid conditions including cardiovascular diseases, diabetes, metabolic syndrome, chronic obstructive pulmonary disease, chronic kidney diseases, and cancer have a higher risk of developing more serious infections [20, 23] .

As of now, there is insufficient evidence to determine how SARS-CoV-2 infection will impact the clinical course of chronic inflammatory conditions such as psoriasis and to estimate potential risks associated with systemic treatment [24] . In Covid-19 patients, but also in SARS and MERS patients, inflammatory cytokines assume a double role: in the first place they stimulate the activation of an effective immune response, while at a later time, in case of failure of the adaptive immunity (mainly Th1-polarized), they mediate the development of an exaggerated systemic inflammation [25] [26] [27] . This "cytokine storm" is

This article is protected by copyright. All rights reserved both ineffective toward the pathogen and detrimental for the body, eventually leading to acute respiratory distress syndrome (ARDS) and potentially to death [28] .

(TNF)-alpha elevation plays a key role in the development of the detrimental inflammatory response correlated to both coronavirus and non coronavirus viral pneumonia [29] . In a model of immunosuppressed macaques infected with MERS-CoV, significantly higher levels of MERS-CoV replication in respiratory tissues and viral shedding, was found. However, despite increased viral replication, pathologic changes in the lungs were significantly lower in immunosuppressed animals [30] . MERS-CoV virus itself caused little damage to the cells that it infected and the tissue damage might be attributed to the overactive inflammatory response. Therefore, it has been hypothesized that treatment for patients with symptomatic COVID-19 would benefit from additional therapy that lessens the inflammatory response, and not be based solely on therapies that are aimed at controlling virus replication. In this context, agents blocking TNF or IL17 pathways could have the potential to improve COVID-19's aberrant immune response and ARDS-related mortality [31] . The exaggerated inflammatory responses (cytokine storm) and increased damage of tissues seen in SARS, MERS and COVID-19 might also be enhanced by patient's comorbidities, namely diabetes, or even by ageing per se. Older adults have elevated levels of pro-inflammatory cytokines, and the term 'inflamm-ageing' was coined to describe this phenomenon. This could partially explain the association between patient's older age and some comorbidities with a worse outcome [34] .

Intriguingly, during SARS outbreak in 2002 and MERS and COVID-19 (so far), no death was reported in transplanted patients or under immunosuppressive treatments, (e.g. cyclosporine, methotrexate, azathioprine) at any age.

In a recent letter, D'Antiga reported 3 immunosuppressed children in Bergamo, Italy, who were tested positive for SARS-CoV-2 but only had a mild disease without any pulmonary involvement [35] . Published data on SARS, MERS and SARS-CoV-2 seem to suggest

This article is protected by copyright. All rights reserved that patients with drug-induced immunosuppression are not at particularly increased risk of severe pulmonary disease compared to the general population.

The role of dermatologists during the pandemic may not be limited to their Dermatology clinics. In the areas of Italy severely affected by the coronavirus outbreak, extra beds have been created in Internal Medicine wards for COVID-19 patients; dermatologists, along with doctors from other medical subspecialties, have therefore been asked to provide assistance to COVID-19 patients in these departments due to the shortage of doctors. For those dermatologists who are now fighting in the front line against COVID-19, a number of challenges need to be faced on a daily basis, the most crucial one being personal protection. As of 20 th March, 3.654 health workers were infected with COVID-19

in Italy, representing about 10% of the total number of positive patients [36] , and 17 physicians died due to SARS-CoV-2 infection [37] . Such appalling data underscore the importance of the availability of protective equipment like medical masks, gloves, eye protection and gowns for medical personnel dealing with infected patients. Shortage of medical masks for health workers due to "panic shopping" from the population may jeopardize the safety of physicians dealing with COVID-19 patients.

A further area where dermatologists are involved is with damages to the skin from personal protective equipment of healthcare professionals and with procedures such as frequent hand washing. Clinical manifestations include acute and chronic irritant dermatitis, secondary infections and possible aggravation of pre-existing cutaneous disorders. Recommendations for preventing these adverse effects have been published [38] . Recommendations for preventing irritant hand dermatitis include avoiding harsh soaps because while these will clear any infectious agent from the skin, at the same time, they destroy the protective barrier that protects us from other pathogens. We need to compensate for the damage we're inflicting on our skin with frequent hand washing or alcohol-based hand sanitizers by putting moisturizer on damp skin [38] .

This article is protected by copyright. All rights reserved

There are several unaddressed issues of SARS-CoV-2 infection for dermatologists. First, dermatologists from Wuhan suggested that skin lesions and derangement of the skin barrier could make it easier for SARS-CoV-2 to transmit via indirect contact [39] .

However, no clear evidence is currently available pointing to any modes of transmission other than inhaling droplets and aerosols, or contact with a contaminated surfaces followed by touching mouth, nose, or eyes [40] . Secondly, it remains to be defined if specific mucosal or skin lesions are associated with SARS-CoV-2 infection. Recalcati S. disease's severity [41] . From Thailand, Joob B et al. reported a case presenting with a skin rash with petechiae associated with low platelet count, initially diagnosed as dengue, suggesting that also vascular lesions may be early signs of the infection [42] . We observed a diffuse papular eruption in a woman with COVID-19 febrile infection, as reported in Figure 1 . Finally, data are currently lacking, as already discussed, concerning the outcome of COVID-19 infection in patients with inflammatory and malignant skin conditions. The course of COVID-19 in patients with immune-mediated diseases like psoriasis receiving different systemic therapies, is completely unknown and may be of special interest to guide the future management of these patients and, more in general, to understand the role of immune response in COVID-19 outcome [43] .

COVID-19 is a new pathogen for humans that is highly contagious, can spread quickly, and is capable of causing enormous health, economic and societal impacts in any setting. Dermatological care is already deeply impacted by the pandemic. The consequences may continue long after the pandemic resolves, and new management modalities for dermatology may originate from the COVID-19 disaster. Learning from experience may help to cope with future major societal changes [44] .

Time to use the p-word? Coronavirus enter dangerous new phase

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Novel Coronavirus-Important Information for Clinicians

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 and Italy: what next? Lancet

Potential impact of seasonal forcing on a SARS-CoV-2 pandemic

Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

COVID-19 cacophony: is there any orchestra conductor?

Accepted Article This article is protected by copyright. All rights reserved

New coronavirus outbreak: Framing questions for pandemic prevention

On the front lines of coronavirus: the Italian response to covid-19

Virtually Perfect? Telemedicine for Covid-19

The growth of teledermatology: Expanding to reach the underserved

Teledermatology as a tool to improve access to care for medically underserved populations: a retrospective descriptive study

Implementation of a dermatology teletriage system to improve access in an underserved clinic: a retrospective study

Impact of store-and-forward (SAF) teledermatology on outpatient dermatologic care: a prospective study in an underserved urban primary care setting

Storeand-forward teledermatology versus in-person visits: a comparison in pediatric teledermatology clinic

Accepted Article This article is protected by copyright. All rights reserved 20

Guidance on the use of biologic agents during COVID-19 outbreak

COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Should patients stop their biologic treatment during the COVID-19 pandemic

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus

IL-17 boosts proinflammatory outcome of antiviral response in human cells

Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Accepted Article This article is protected by copyright. All rights reserved

Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice

Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques. Front Immunol

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Age-dependent dysregulation of innate immunity

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

Integrated surveillance of COVID-19 in Italy

Elenco dei Medici caduti nel corso dell'epidemia di Covid-19

Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019

Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Cutaneous manifestations in COVID-19: a first perspective

COVID-19 can present with a rash and be mistaken for

Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia

This article is protected by copyright. All rights reserved

